Sign In
Buy RHHBY
$51.57
+2.51 (+5.12%)
At Close: Jun 04, 2026
Roche's Alzheimer's drug fails to meet goal in long awaited trial
01:13am, Monday, 14'th Nov 2022
Roche said its Alzheimer's drug candidate could not clearly be shown to slow dementia progression in two drug trials, failing to draw level with a recent development success by rivals Biogen and Eisai
Trading Ideas On The Upcoming CTAD 2022 Conference
03:27pm, Wednesday, 02'nd Nov 2022
The Clinical Trials on Alzheimer's Conference will take place from November 29, 2022 to December 2, 2022. Representatives of several listed companies will present data, including Eisai, Anavex, BioVie
Will AbbVie's Immunology Drugs Continue to Drive Q3 Earnings?
02:18pm, Wednesday, 26'th Oct 2022
AbbVie's (ABBV) third-quarter performance is expected to reflect the impact of strong demand for immunology and aesthetics products.
Basel, 19 October 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS® (ocrelizumab) data and continued research into neuromyelitis optica spectrum disorder (NMOSD) will be pre
Roche (RHHBY) Q3 Revenues Dip on Lower COVID-19-Related Sales
03:03pm, Tuesday, 18'th Oct 2022
Roche's (RHHBY) performance in the third quarter was pretty ho-hum as COVID-19-related sales continue to decline.
Roche to present new data from its expanding neuromuscular disease portfolio at World Muscle Society 2022
01:00am, Wednesday, 05'th Oct 2022
Basel, 05 October 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from its industry-leading neuromuscular portfolio will be presented at the World Muscle Society (WMS) congress
What's Happening With Roche (RHHBY) Stock?
10:00am, Friday, 30'th Sep 2022
This can be attributed to Biogen's success with its Alzheimer's treatment - Lecanemab - in late-stage clinical trials.
NVS vs. RHHBY: Which Stock Should Value Investors Buy Now?
12:47pm, Thursday, 29'th Sep 2022
NVS vs. RHHBY: Which Stock Is the Better Value Option?
Roche: New Drugs Will Outpace Biosimilar Competition
11:21am, Thursday, 29'th Sep 2022
We comment on the latest company's development after its Pharma Day. Is Roche's dividend at risk? We don't believe so.
Analysis: Alzheimer's drug breakthrough big boost for Roche, Eli Lilly
10:03am, Wednesday, 28'th Sep 2022
The results of a key Alzheimer's drug trial on Wednesday have reignited decades-old hopes that targeting a particular protein helps arrest the progression of the fatal brain disease, giving a big boos
Roche's (RHHBY) Vabysmo Gets Approval for nAMD & DME in Europe
01:32pm, Monday, 19'th Sep 2022
The European Commission approves Roche's (RHHBY) Vabysmo for treating neovascular or wet age-related macular degeneration and visual impairment due to diabetic macular edema.
Roche's vision-loss drug Vabysmo gets EU nod
02:01am, Monday, 19'th Sep 2022
Roche Holding AG said Monday that its vision-loss treatment Vabysmo has been approved in the European Union after successful phase-3 study data.
Roche Is Trying To Break Out (Technical Analysis)
12:32pm, Thursday, 15'th Sep 2022
Roche bottomed on June 16, reached my previously set target, and is forming a sound base from which it could attempt to break out. The stock is a leader in its industry despite underperforming the bro
AstraZeneca, Eli Lilly and Roche among pharmaceutical companies upgraded for high returns on R&D investments, analysts say
07:48am, Wednesday, 14'th Sep 2022
Shares in pharmaceutical giants including Roche, Novo Nordisk, Eli Lilly and AstraZeneca were little changed Wednesday despite getting a ratings boost from analysts at Berenberg, who cited respective
Roche's (RHHBY) sBLA For Polivy Combo Accepted by FDA
01:33pm, Tuesday, 16'th Aug 2022
Roche's (RHHBY) sBLA seeking approval for the use of Polivy in combination with R-CHP for previously untreated diffuse large B-cell lymphoma in adults has been accepted in the United States.
